Pirtobrutinib Demonstrates Strong Response Rates for Previously Treated CLL/SLL
Strong response rates were observed with pirtobrutinib across dose levels to treat patients with chronic lymphocytic leukemia and small lymphocytic lymphoma ion a phase 1/2 study.
Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics
The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.
